SPY319.34+7.98 2.56%
DIA271.54+8.21 3.12%
IXIC9,814.08+198.27 2.06%

Barclays Maintains Overweight on Syndax Pharmaceuticals, Lowers Price Target to $23

Barclays maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Overweight and lowers the price target from $25 to $23.

Benzinga · 05/22/2020 11:35

Barclays maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Overweight and lowers the price target from $25 to $23.